TY  - JOUR
AU  - Munjas, Jelena
AU  - Sopić, Miron
AU  - Joksić, Ivana
AU  - Prosenc Zmrzljak, Ursula
AU  - Karadžov-Orlić, Nataša
AU  - Košir, Rok
AU  - Egić, Amira
AU  - Miković, Željko
AU  - Ninić, Ana
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3669
PB  - Elsevier
T2  - Clinical Biochemistry
T1  - Corrigendum to “Placenta-specific plasma miR518b is a potential biomarker for preeclampsia” [Clin. Biochem. 79 (2020) 28–33]
VL  - 85
SP  - 57
EP  - 57
DO  - 10.1016/j.clinbiochem.2020.08.011
ER  - 

@article{
author = "Munjas, Jelena and Sopić, Miron and Joksić, Ivana and Prosenc Zmrzljak, Ursula and Karadžov-Orlić, Nataša and Košir, Rok and Egić, Amira and Miković, Željko and Ninić, Ana and Spasojević-Kalimanovska, Vesna",
year = "2020",
publisher = "Elsevier",
journal = "Clinical Biochemistry",
title = "Corrigendum to “Placenta-specific plasma miR518b is a potential biomarker for preeclampsia” [Clin. Biochem. 79 (2020) 28–33]",
volume = "85",
pages = "57-57",
doi = "10.1016/j.clinbiochem.2020.08.011"
}

Munjas, J., Sopić, M., Joksić, I., Prosenc Zmrzljak, U., Karadžov-Orlić, N., Košir, R., Egić, A., Miković, Ž., Ninić, A.,& Spasojević-Kalimanovska, V.. (2020). Corrigendum to “Placenta-specific plasma miR518b is a potential biomarker for preeclampsia” [Clin. Biochem. 79 (2020) 28–33]. in Clinical Biochemistry
Elsevier., 85, 57-57.
https://doi.org/10.1016/j.clinbiochem.2020.08.011

Munjas J, Sopić M, Joksić I, Prosenc Zmrzljak U, Karadžov-Orlić N, Košir R, Egić A, Miković Ž, Ninić A, Spasojević-Kalimanovska V. Corrigendum to “Placenta-specific plasma miR518b is a potential biomarker for preeclampsia” [Clin. Biochem. 79 (2020) 28–33]. in Clinical Biochemistry. 2020;85:57-57.
doi:10.1016/j.clinbiochem.2020.08.011 .

Munjas, Jelena, Sopić, Miron, Joksić, Ivana, Prosenc Zmrzljak, Ursula, Karadžov-Orlić, Nataša, Košir, Rok, Egić, Amira, Miković, Željko, Ninić, Ana, Spasojević-Kalimanovska, Vesna, "Corrigendum to “Placenta-specific plasma miR518b is a potential biomarker for preeclampsia” [Clin. Biochem. 79 (2020) 28–33]" in Clinical Biochemistry, 85 (2020):57-57,
https://doi.org/10.1016/j.clinbiochem.2020.08.011 . .

TY  - JOUR
AU  - Joksić, Ivana
AU  - Miković, Željko
AU  - Filimonović, Dejan
AU  - Munjas, Jelena
AU  - Karadžov-Orlić, Nataša
AU  - Egić, Amira
AU  - Joksić, Gordana
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3618
AB  - Background:Recurrent pregnancy loss (RPL) is a heterogeneous condition affecting up to 5% of women of reproductive age. Inherited thrombophilia have been postulated as one  of  the  causes  of  RPL.  Here  we  examined  the  prevalence  of  nine  thrombophilic  gene  polymorphisms  among women  with  history  of  recurrent  miscarriages  and  fertile controls.Methods:The study included 70 women with history of at least  three  early  pregnancy  losses  and  31  fertile  controls with  no  miscarriages.  We  investigated  mutations  in  genes responsible  for  clotting  and  fibrinolysis,  including  factor  V(FV) Leiden, FV H1299R, factor II (FII) G20210A, methyl-ene  tetrahydrofolate  reductase  (MTHFR)  C677T  and A1298C,  factor  XIII  (FXIII)  V34L,  plasminogen  activator inhibitor-1 (PAI-1) 4G/5G and endothelial protein C receptor  (EPCR)  H1  and  H3  haplotypes  using  reverse  polymerase  chain  reaction  ViennaLab  cardiovascular  disease StrippAssays. Results:Our  results  showed  no  significant  increase  inprevalence  of  tested  polymorphisms  in  women  with  RPL. However, relative risk for PRL among women heterozygousfor FXIII V34L was 2.81 times increased (OR 2.81, 95% CI1.15–6.87,  P=0.023).  Haplotype  analysis  showed  that combined  presence  of  high-risk  genotypes  for  FXIII  andPAI-1  significantly  increases  risk  for  RPL  (OR  13.98,  CI95% 1.11–17.46, P=0.044).Conclusions:This  is  the  first  study  in  Serbian  population that investigated prevalence of FVR2, A1298C, FXIII V34Land  EPCR  gene  variants.  Compound  heterozygosity  forFXIII V34L and PAI-1 4G is significant risk factor for recur-rent miscarriage. Our results should be viewed in context of small case-control study, so further large prospective studies are need for confirmation of our findings.
AB  - Uvod: Ponavljani spontani pobačaji (PSP) su etiološki heterogeni i javljaju se kod 5% parova u reproduktivnom period. Jedan od mogućih uzroka PSP su i nasledne trombofilije. U okviru ove studije analizirali smo učestalost devet trombofilnih polimorfizama kod pacijentkinja sa ponavljanim spontanim pobačajima. Metode: Ispitanici su u studiji podeljeni u dve grupe na osnovu anamnestičkih podataka o broju spontanih pobačaja (70 u grupi sa PSP i 31 u kontrolnoj grupi). Ispitivani su sledeći genski polimorfizmi: faktor V Lajden (FVL), FVR2, faktor II (FII) G21210A, metilentetrahidrofolat reduktaza (MTHFR) C677T i A1298C polimorfizmi, inhibitor aktivatora plazminogena 1 (PAI-1) 4G/5G, faktor XIII (FXIII) V34L i endotelni protein C receptor (EPRC) H1, H2 i H3 haplotipovi. Za detekciju navedenih polimorfizama je korišćena metoda multipleks reakcije lančanog umnožavanja i reverzne hibridizacije na ViennaLab stripovima. Rezultati: Dobijeni rezultati nisu pokazali povećanu učestalost ispitivanih polimorfizama u grupi sa PSP. Posmatrajući uticaj pojedinačnih polimorfizama na ishod trudnoće pokazano je da polimorfizam FXIII V34L povećava rizik za ponavljane spontane pobačaje (OR 2,81, 95%CI 1,15-6,87, P=0,023). Analizom haplotipova ustanovljeno je da kombinovano prisustvo V34L i PAI-1 4G varijanti značajno povećava rizik za PSP (OR 13,98, CI 95% 1,11-17,46, P=0,044). Zaključak: Ovo je prva studija koja je ispitivala prevalencu FVR2, A1298C, FXIII V34L and EPCR polimorfizama u populaciji žena iz Srbije. Složeni heterozigoti za FXIII V34L i PAI-1 4G polimorfizme imaju značajno povišen rizik sa ponavljane gubitke trudnoće. Radi potvrde dobijenih rezultata potrebne su veće prospektivne studije.
PB  - Beograd : Društvo medicinskih biohemičara Srbije
T2  - Journal of Medical Biochemistry
T1  - Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in serbian population
T1  - Kombinovano prisustvo genskih polimorfizma faktora koagulacije XIII V34L i inhibitora plazminogen aktivatora 1 4G/5G značajno utiče na rizik od spontanog pobačaja u srpskoj populaciji
VL  - 39
IS  - 2
SP  - 199
EP  - 207
DO  - 10.2478/jomb-2019-0028
ER  - 

@article{
author = "Joksić, Ivana and Miković, Željko and Filimonović, Dejan and Munjas, Jelena and Karadžov-Orlić, Nataša and Egić, Amira and Joksić, Gordana",
year = "2020",
abstract = "Background:Recurrent pregnancy loss (RPL) is a heterogeneous condition affecting up to 5% of women of reproductive age. Inherited thrombophilia have been postulated as one  of  the  causes  of  RPL.  Here  we  examined  the  prevalence  of  nine  thrombophilic  gene  polymorphisms  among women  with  history  of  recurrent  miscarriages  and  fertile controls.Methods:The study included 70 women with history of at least  three  early  pregnancy  losses  and  31  fertile  controls with  no  miscarriages.  We  investigated  mutations  in  genes responsible  for  clotting  and  fibrinolysis,  including  factor  V(FV) Leiden, FV H1299R, factor II (FII) G20210A, methyl-ene  tetrahydrofolate  reductase  (MTHFR)  C677T  and A1298C,  factor  XIII  (FXIII)  V34L,  plasminogen  activator inhibitor-1 (PAI-1) 4G/5G and endothelial protein C receptor  (EPCR)  H1  and  H3  haplotypes  using  reverse  polymerase  chain  reaction  ViennaLab  cardiovascular  disease StrippAssays. Results:Our  results  showed  no  significant  increase  inprevalence  of  tested  polymorphisms  in  women  with  RPL. However, relative risk for PRL among women heterozygousfor FXIII V34L was 2.81 times increased (OR 2.81, 95% CI1.15–6.87,  P=0.023).  Haplotype  analysis  showed  that combined  presence  of  high-risk  genotypes  for  FXIII  andPAI-1  significantly  increases  risk  for  RPL  (OR  13.98,  CI95% 1.11–17.46, P=0.044).Conclusions:This  is  the  first  study  in  Serbian  population that investigated prevalence of FVR2, A1298C, FXIII V34Land  EPCR  gene  variants.  Compound  heterozygosity  forFXIII V34L and PAI-1 4G is significant risk factor for recur-rent miscarriage. Our results should be viewed in context of small case-control study, so further large prospective studies are need for confirmation of our findings., Uvod: Ponavljani spontani pobačaji (PSP) su etiološki heterogeni i javljaju se kod 5% parova u reproduktivnom period. Jedan od mogućih uzroka PSP su i nasledne trombofilije. U okviru ove studije analizirali smo učestalost devet trombofilnih polimorfizama kod pacijentkinja sa ponavljanim spontanim pobačajima. Metode: Ispitanici su u studiji podeljeni u dve grupe na osnovu anamnestičkih podataka o broju spontanih pobačaja (70 u grupi sa PSP i 31 u kontrolnoj grupi). Ispitivani su sledeći genski polimorfizmi: faktor V Lajden (FVL), FVR2, faktor II (FII) G21210A, metilentetrahidrofolat reduktaza (MTHFR) C677T i A1298C polimorfizmi, inhibitor aktivatora plazminogena 1 (PAI-1) 4G/5G, faktor XIII (FXIII) V34L i endotelni protein C receptor (EPRC) H1, H2 i H3 haplotipovi. Za detekciju navedenih polimorfizama je korišćena metoda multipleks reakcije lančanog umnožavanja i reverzne hibridizacije na ViennaLab stripovima. Rezultati: Dobijeni rezultati nisu pokazali povećanu učestalost ispitivanih polimorfizama u grupi sa PSP. Posmatrajući uticaj pojedinačnih polimorfizama na ishod trudnoće pokazano je da polimorfizam FXIII V34L povećava rizik za ponavljane spontane pobačaje (OR 2,81, 95%CI 1,15-6,87, P=0,023). Analizom haplotipova ustanovljeno je da kombinovano prisustvo V34L i PAI-1 4G varijanti značajno povećava rizik za PSP (OR 13,98, CI 95% 1,11-17,46, P=0,044). Zaključak: Ovo je prva studija koja je ispitivala prevalencu FVR2, A1298C, FXIII V34L and EPCR polimorfizama u populaciji žena iz Srbije. Složeni heterozigoti za FXIII V34L i PAI-1 4G polimorfizme imaju značajno povišen rizik sa ponavljane gubitke trudnoće. Radi potvrde dobijenih rezultata potrebne su veće prospektivne studije.",
publisher = "Beograd : Društvo medicinskih biohemičara Srbije",
journal = "Journal of Medical Biochemistry",
title = "Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in serbian population, Kombinovano prisustvo genskih polimorfizma faktora koagulacije XIII V34L i inhibitora plazminogen aktivatora 1 4G/5G značajno utiče na rizik od spontanog pobačaja u srpskoj populaciji",
volume = "39",
number = "2",
pages = "199-207",
doi = "10.2478/jomb-2019-0028"
}

Joksić, I., Miković, Ž., Filimonović, D., Munjas, J., Karadžov-Orlić, N., Egić, A.,& Joksić, G.. (2020). Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in serbian population. in Journal of Medical Biochemistry
Beograd : Društvo medicinskih biohemičara Srbije., 39(2), 199-207.
https://doi.org/10.2478/jomb-2019-0028

Joksić I, Miković Ž, Filimonović D, Munjas J, Karadžov-Orlić N, Egić A, Joksić G. Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in serbian population. in Journal of Medical Biochemistry. 2020;39(2):199-207.
doi:10.2478/jomb-2019-0028 .

Joksić, Ivana, Miković, Željko, Filimonović, Dejan, Munjas, Jelena, Karadžov-Orlić, Nataša, Egić, Amira, Joksić, Gordana, "Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in serbian population" in Journal of Medical Biochemistry, 39, no. 2 (2020):199-207,
https://doi.org/10.2478/jomb-2019-0028 . .

TY  - JOUR
AU  - Munjas, Jelena
AU  - Sopić, Miron
AU  - Joksić, Ivana
AU  - Prosenc Zmrzljak, Ursula
AU  - Karadžov-Orlić, Nataša
AU  - Košir, Rok
AU  - Egić, Amira
AU  - Miković, Željko
AU  - Ninić, Ana
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3602
AB  - Introduction: MicroRNAs have a significant role in the pathogenesis of preeclampsia. Circulating microRNAs could represent a potential biomarker for preeclampsia. The aim of this study was to evaluate plasma miR210-3p and miR518b in preeclampsia and healthy pregnancy for the first time by digital droplet PCR (ddPCR). Methods: Thirty-six pregnant women (seventeen healthy pregnancies, nineteen preeclampsia patients) were involved from the Clinic for Gynaecology and Obstetrics “Narodni front” in Belgrade, Serbia. Plasma miR210-3p, miR518b and cel-miR-39 as a spike-in control were measured by ddPCR. Results: MiR518b was significantly elevated in preeclampsia compared to a healthy pregnancy (P = 0.034; 0.302(0.217–0.421) vs. 0.171(0.110–0.266)). MiR210-3p showed no significant difference between the two groups (P = 0.951). The adjustment of miR518b was made for a gestational age and smoking status and the difference between the preeclampsia and healthy pregnancy group was more significant (P = 0.026; 0.300(0.216–0.419) vs. 0.172(0.121–0.245)). Plasma miR-518b was significantly higher in the group of preeclampsia patients with proteinuria above the 75th percentile for the group (P=0.033), in women who smoked (P=0.039), and was positively related to uric acid in preeclampsia (P = 0.018, r = 0.536). Plasma miR518b was able to significantly discriminate between preeclampsia and healthy pregnancy, yielding AUC of 0.712 (95%CI:0.539–0.891), P = 0.028. Conclusions: In this study plasma microRNA were measured for the first time in preeclampsia and healthy pregnancies with ddPCR. Placenta-specific miR-518b could serve as a potential biomarker for discriminating preeclampsia and healthy pregnancy, which should be confirmed on a larger study population. This study has failed to confirm the same potential for miR210-3p.
PB  - Elsevier
T2  - Clinical Biochemistry
T1  - Placenta-specific plasma miR518b is a potential biomarker for preeclampsia
VL  - 79
SP  - 28
EP  - 33
DO  - 10.1016/j.clinbiochem.2020.02.012
ER  - 

@article{
author = "Munjas, Jelena and Sopić, Miron and Joksić, Ivana and Prosenc Zmrzljak, Ursula and Karadžov-Orlić, Nataša and Košir, Rok and Egić, Amira and Miković, Željko and Ninić, Ana and Spasojević-Kalimanovska, Vesna",
year = "2020",
abstract = "Introduction: MicroRNAs have a significant role in the pathogenesis of preeclampsia. Circulating microRNAs could represent a potential biomarker for preeclampsia. The aim of this study was to evaluate plasma miR210-3p and miR518b in preeclampsia and healthy pregnancy for the first time by digital droplet PCR (ddPCR). Methods: Thirty-six pregnant women (seventeen healthy pregnancies, nineteen preeclampsia patients) were involved from the Clinic for Gynaecology and Obstetrics “Narodni front” in Belgrade, Serbia. Plasma miR210-3p, miR518b and cel-miR-39 as a spike-in control were measured by ddPCR. Results: MiR518b was significantly elevated in preeclampsia compared to a healthy pregnancy (P = 0.034; 0.302(0.217–0.421) vs. 0.171(0.110–0.266)). MiR210-3p showed no significant difference between the two groups (P = 0.951). The adjustment of miR518b was made for a gestational age and smoking status and the difference between the preeclampsia and healthy pregnancy group was more significant (P = 0.026; 0.300(0.216–0.419) vs. 0.172(0.121–0.245)). Plasma miR-518b was significantly higher in the group of preeclampsia patients with proteinuria above the 75th percentile for the group (P=0.033), in women who smoked (P=0.039), and was positively related to uric acid in preeclampsia (P = 0.018, r = 0.536). Plasma miR518b was able to significantly discriminate between preeclampsia and healthy pregnancy, yielding AUC of 0.712 (95%CI:0.539–0.891), P = 0.028. Conclusions: In this study plasma microRNA were measured for the first time in preeclampsia and healthy pregnancies with ddPCR. Placenta-specific miR-518b could serve as a potential biomarker for discriminating preeclampsia and healthy pregnancy, which should be confirmed on a larger study population. This study has failed to confirm the same potential for miR210-3p.",
publisher = "Elsevier",
journal = "Clinical Biochemistry",
title = "Placenta-specific plasma miR518b is a potential biomarker for preeclampsia",
volume = "79",
pages = "28-33",
doi = "10.1016/j.clinbiochem.2020.02.012"
}

Munjas, J., Sopić, M., Joksić, I., Prosenc Zmrzljak, U., Karadžov-Orlić, N., Košir, R., Egić, A., Miković, Ž., Ninić, A.,& Spasojević-Kalimanovska, V.. (2020). Placenta-specific plasma miR518b is a potential biomarker for preeclampsia. in Clinical Biochemistry
Elsevier., 79, 28-33.
https://doi.org/10.1016/j.clinbiochem.2020.02.012

Munjas J, Sopić M, Joksić I, Prosenc Zmrzljak U, Karadžov-Orlić N, Košir R, Egić A, Miković Ž, Ninić A, Spasojević-Kalimanovska V. Placenta-specific plasma miR518b is a potential biomarker for preeclampsia. in Clinical Biochemistry. 2020;79:28-33.
doi:10.1016/j.clinbiochem.2020.02.012 .

Munjas, Jelena, Sopić, Miron, Joksić, Ivana, Prosenc Zmrzljak, Ursula, Karadžov-Orlić, Nataša, Košir, Rok, Egić, Amira, Miković, Željko, Ninić, Ana, Spasojević-Kalimanovska, Vesna, "Placenta-specific plasma miR518b is a potential biomarker for preeclampsia" in Clinical Biochemistry, 79 (2020):28-33,
https://doi.org/10.1016/j.clinbiochem.2020.02.012 . .

TY  - JOUR
AU  - Toljić, Mina
AU  - Egić, Amira
AU  - Munjas, Jelena
AU  - Orlić, Nataša Karadzov
AU  - Milovanović, Zagorka
AU  - Radenković, Aleksandra
AU  - Vuceljić, Jovana
AU  - Joksić, Ivana
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2808
AB  - We investigated whether gestational diabetes mellitus (GDM) and gestational arterial hypertension (GH) are associated with increased oxidative stress and DNA damage. Study included 3 groups of pregnant women (GDM, GH and control). DNA damage biomarkers (micronuclei MNi, nucleoplasmic bridges NPBs and nuclear buds NBUDs) were assessed by cytokinesis-block micronucleus cytome assay. Oxidative stress levels were evaluated by analyzing malondialdehyde equivalents (TBARS) and 8-hydroxy-2'deoxyguanosine (8-OHdG). Genotoxic effect of methyldopa, drug used to treat GH, was evaluated in in vitro experiment. TBARS levels, MNi, NPBs and NBUDs frequencies were significantly increased in both GDM and GH group. Concentrations of 8-OHdG were significantly higher in GDM than in other groups. Since methyldopa did not affect MNi, NPBs and NBUDs frequencies, nor TBARS and 8-OHdG levels, we concluded that methyldopa has no genotoxic effect. Thus, even when hyperglycemia or hypertension are present only during pregnancy they induce oxidative stress, DNA damage and chromosomal aberrations.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Research in Microbiology
T1  - Increased oxidative stress and cytokinesis-block micronucleus cytome assay parameters in pregnant women with gestational diabetes mellitus and gestational arterial hypertension
VL  - 71
SP  - 55
EP  - 62
DO  - 10.1016/j.reprotox.2017.04.002
ER  - 

@article{
author = "Toljić, Mina and Egić, Amira and Munjas, Jelena and Orlić, Nataša Karadzov and Milovanović, Zagorka and Radenković, Aleksandra and Vuceljić, Jovana and Joksić, Ivana",
year = "2017",
abstract = "We investigated whether gestational diabetes mellitus (GDM) and gestational arterial hypertension (GH) are associated with increased oxidative stress and DNA damage. Study included 3 groups of pregnant women (GDM, GH and control). DNA damage biomarkers (micronuclei MNi, nucleoplasmic bridges NPBs and nuclear buds NBUDs) were assessed by cytokinesis-block micronucleus cytome assay. Oxidative stress levels were evaluated by analyzing malondialdehyde equivalents (TBARS) and 8-hydroxy-2'deoxyguanosine (8-OHdG). Genotoxic effect of methyldopa, drug used to treat GH, was evaluated in in vitro experiment. TBARS levels, MNi, NPBs and NBUDs frequencies were significantly increased in both GDM and GH group. Concentrations of 8-OHdG were significantly higher in GDM than in other groups. Since methyldopa did not affect MNi, NPBs and NBUDs frequencies, nor TBARS and 8-OHdG levels, we concluded that methyldopa has no genotoxic effect. Thus, even when hyperglycemia or hypertension are present only during pregnancy they induce oxidative stress, DNA damage and chromosomal aberrations.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Research in Microbiology",
title = "Increased oxidative stress and cytokinesis-block micronucleus cytome assay parameters in pregnant women with gestational diabetes mellitus and gestational arterial hypertension",
volume = "71",
pages = "55-62",
doi = "10.1016/j.reprotox.2017.04.002"
}

Toljić, M., Egić, A., Munjas, J., Orlić, N. K., Milovanović, Z., Radenković, A., Vuceljić, J.,& Joksić, I.. (2017). Increased oxidative stress and cytokinesis-block micronucleus cytome assay parameters in pregnant women with gestational diabetes mellitus and gestational arterial hypertension. in Research in Microbiology
Pergamon-Elsevier Science Ltd, Oxford., 71, 55-62.
https://doi.org/10.1016/j.reprotox.2017.04.002

Toljić M, Egić A, Munjas J, Orlić NK, Milovanović Z, Radenković A, Vuceljić J, Joksić I. Increased oxidative stress and cytokinesis-block micronucleus cytome assay parameters in pregnant women with gestational diabetes mellitus and gestational arterial hypertension. in Research in Microbiology. 2017;71:55-62.
doi:10.1016/j.reprotox.2017.04.002 .

Toljić, Mina, Egić, Amira, Munjas, Jelena, Orlić, Nataša Karadzov, Milovanović, Zagorka, Radenković, Aleksandra, Vuceljić, Jovana, Joksić, Ivana, "Increased oxidative stress and cytokinesis-block micronucleus cytome assay parameters in pregnant women with gestational diabetes mellitus and gestational arterial hypertension" in Research in Microbiology, 71 (2017):55-62,
https://doi.org/10.1016/j.reprotox.2017.04.002 . .